2025
Addressing Peri-Device Leaks in Next-Generation Transcatheter Left Atrial Appendage Occluders: An Open Question
Roshanfar M, Jang S, Sinusas A, Wong S, Mosadegh B. Addressing Peri-Device Leaks in Next-Generation Transcatheter Left Atrial Appendage Occluders: An Open Question. Surgeries 2025, 6: 15. DOI: 10.3390/surgeries6010015.Peer-Reviewed Original ResearchPeri-device leakLeft atrial appendageFDA-approved devicesRisk of thrombo-embolic eventsNon-valvular atrial fibrillationLeft atrial appendage anatomyLong-term anticoagulationPercutaneous LAA occlusionCHA2DS2-VASc scoreThrombo-embolic eventsIncreased risk of strokeRisk of strokeCircular cross-sectionLeft atrial appendage occluderSystemic embolismAnticoagulant therapyLAA occlusionObservational registryCHA2DS2-VAScNon-pharmacological alternativeAdverse eventsAtrial fibrillationAtrial appendageClinical dataIncreased risk
2018
Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials
Romero J, Cerrud-Rodriguez R, Diaz J, Michaud G, Taveras J, Alviz I, Grupposo V, Cerna L, Avendano R, Kumar S, Kirchhof P, Natale A, Di Biase L. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. EP Europace 2018, 20: 1612-1620. PMID: 29982383, DOI: 10.1093/europace/euy133.Peer-Reviewed Original ResearchConceptsNon-valvular atrial fibrillationUninterrupted direct oral anticoagulantsUninterrupted vitamin K antagonistsDirect oral anticoagulantsVitamin K antagonistsMajor bleeding eventsSilent cerebral infarctionThrombo-embolic eventsCatheter ablationBleeding eventsAtrial fibrillationMajor bleedingK antagonistsOral anticoagulantsSystematic reviewBrain magnetic resonance imagingMinor bleeding eventsFirst-line therapyParoxysmal atrial fibrillationRandom-effects modelMagnetic resonance imagingFixed-effects modelMinor bleedingCerebral infarctionLine therapy
2006
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma
Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs 2006, 24: 135-140. PMID: 16502351, DOI: 10.1007/s10637-006-5934-5.Peer-Reviewed Original ResearchConceptsPathologic complete response rateThrombo-embolic eventsParallel design studyModality therapyResponse rateAdvanced esophageal cancer patientsRandomized phase IIComplete response rateEvidence of diseaseProgression-free survivalEsophageal cancer patientsOverall response ratePhase IIAdjuvant paclitaxelConcurrent radiotherapyEligible patientsPreoperative treatmentMusculoskeletal toxicityOverall survivalResectable adenocarcinomaDisease relapsePreoperative stagingTreatment armsDisease improvementContinuous infusion
2005
Treatment of hot flushes in breast and prostate cancer
Adelson KB, Loprinzi CL, Hershman DL. Treatment of hot flushes in breast and prostate cancer. Expert Opinion On Pharmacotherapy 2005, 6: 1095-1106. PMID: 15957964, DOI: 10.1517/14656566.6.7.1095.Peer-Reviewed Original ResearchMeSH KeywordsAminesAntineoplastic Agents, HormonalBreast NeoplasmsCimicifugaContraindicationsCyclohexanecarboxylic AcidsDrug Therapy, CombinationElectroacupunctureExcitatory Amino Acid AntagonistsFemaleGabapentingamma-Aminobutyric AcidHormone Replacement TherapyHot FlashesHumansMaleNeoplasms, Hormone-DependentOrchiectomyParoxetinePhytotherapyPlant PreparationsProstatic NeoplasmsRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsConceptsHormone replacement therapyHot flushesBreast cancerReplacement therapyProstate cancerSelective serotonin reuptake inhibitorsChemotherapy-induced menopauseMenopausal age womenMainstay of treatmentThrombo-embolic eventsSerotonin reuptake inhibitorsHealthy menopausal womenCommon health problemHot flush symptomsQuality of lifeMedical castrationHormonal therapyOvarian suppressionAndrogen ablationPerimenopausal periodNonhormonal agentsReuptake inhibitorsSignificant morbidityCancer survivorsMenopausal women
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply